Visceral Shred

Archival Status

Tesamorelin and Ipamorelin address visceral adiposity through complementary but distinct mechanisms — tesamorelin through direct GHRH receptor activation with clinically validated efficacy for visceral fat reduction, and Ipamorelin through selective GH pulse amplification without the cortisol and prolactin elevation associated with earlier GHRPs. Tesamorelin is the only FDA-approved GHRH analogue, indicated for HIV-associated lipodystrophy (HAART-induced visceral adiposity). Its approval is based on Phase 3 randomized controlled trial data demonstrating statistically significant reductions in visceral adipose tissue (VAT) measured by CT scan — a clinical endpoint more rigorous than simple BMI or body weight reduction. Tesamorelin's mechanism involves stimulation of pituitary GH secretion, which preferentially mobilizes visceral fat through GH receptor-mediated lipolysis in mesenteric and omental adipose tissue. The selectivity of tesamorelin for visceral fat is mechanistically significant. Visceral adipocytes have higher GH receptor density than subcutaneous fat cells, making them particularly responsive to GH-mediated lipolytic signaling. Research consistently shows tesamorelin reduces VAT without significantly affecting subcutaneous adipose tissue — a distinction relevant to metabolic risk, since visceral fat is the primary contributor to insulin resistance, dyslipidemia, and cardiovascular disease risk. Ipamorelin's role in this protocol is to amplify GH pulse amplitude via the ghrelin receptor axis without introducing cortisol or prolactin elevation. This allows a more complete activation of the GH secretory response than tesamorelin alone while maintaining the hormonal specificity that makes Ipamorelin the preferred GHRP for extended research protocols. Clinical applications studied include: HIV lipodystrophy, age-related visceral fat accumulation, metabolic syndrome with central obesity, and non-alcoholic fatty liver disease linked to visceral adiposity. Standard research protocols typically run 6–12 months given the progressive nature of VAT reduction. Tesamorelin is administered daily via subcutaneous injection, while Ipamorelin is typically dosed 2–3 times daily or pre-sleep.